A randomized phase l study on TS-1+CDDP+CPT-11(IPS) therapy for patients with advanced/metastatic gastric cancer(HERBIS-4A) (OGSG 1106) - OGSG 1106 HER2 Based Strategy in Stomach Cancer(HERBIS-4B) (OGSG 1106)

Osaka Gastroestinal cancer chemotherapy Study Group (OGSG)0 个研究点目标入组 12 人开始时间: 2011年12月10日最近更新: 2023年10月17日

适应症

试验速览

阶段: 1 期
状态: 已完成
发起方
入组人数: 12

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

With reference to the number of grade 4 or higher adverse event occurrences, the recommended doses were determined to be irinotecan 100 mg/m2, cisplatin 60 mg/m2, and S-1 80 mg/m2; the maximum tolerated doses were irinotecan 125 mg/m2, cisplatin 60 mg/m2, and S-1 80 mg/m2.

研究设计

研究类型: Interventional

入排标准

年龄范围: 20years-old 至 75years-old（—）
性别: All

入选标准

未提供

排除标准

•1)with active double cancers whose disease free period is shorter than 5 years Carcinoma in situ can be included 2)with a history of severe allergy against medicines 3)with severe diarrhea (more than 4 times/day) or watery stool 4)with body temperature over 38 degrees Celsius and/or infectious disease which needs therapy 5)with severe myelo-dysfunction, renal dysfunction and/or liver dysfunction 6)with other sever diseases a)interstitial pneumonitis, pulmonary fibrosis or severe emphysema b)cardiac failure, cardiac infarction, angina pectoris c)renal dysfunction d)liver dysfunction e)intestinal paralysis, ileus f)jaundice g)uncontrolled DM 7)with HBs (+) 8)patients whom administered Flucitosine or Athazanavil sulfate 9)patients whom administered Fenitoin and/or Warfarin 10)general administration of steroids 11)women who are pregnant or expect to be pregnant, or nursing female 12)patients whom doctor in chief decides not to register to this study due to psychological disease or symptoms 13)patients whom doctor in chief decides not to register to this study due to other reasons

研究者

发起方

Osaka Gastroestinal cancer chemotherapy Study Group (OGSG)

相似试验

已完成

1 期

Study of combination chemotherapy of CPT-11/S-1 after anthracycline and taxane in recurrent or metastatic breast cancer (JBCRG-M01)Reccurent or metastatic breast cancer

JPRN-UMIN000000517Japan Breast Cancer Research Group (JBCRG)12

进行中（未招募）

1 期

A Clinical Study of TQB3823 in Patients With Advanced Malignant TumorAdvanced Solid Tumor

NCT05021367Chia Tai Tianqing Pharmaceutical Group Co., Ltd.164

已完成

1 期

A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant TumorAdvanced Malignant Neoplasm

NCT05997342Chia Tai Tianqing Pharmaceutical Group Co., Ltd.36

已完成

1 期

A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or LymphomasAdvanced Solid TumorsLymphomas

NCT01512758Millennium Pharmaceuticals, Inc.36

已完成

1 期

A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple MyelomaMultiple Myeloma

NCT00915408King's College Hospital NHS Trust32